A new study reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

Vera Therapeutics has come a long way towards the development of Atacicept for the treatment of patients with IgAN. Read more ...

In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR ...

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Antibodies from the mpox vaccine Jynneos appear to drop off after a few months, and boosters may be needed, according to a small new study. Researchers from Harvard Medical School found that mpox ...

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government's Advanced Research Projects Agency for Health (ARPA-H) to develop a ...

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell related abnormalities. Pyroptosis is a type of regulated ...